Zidovudine News and Research

RSS
Zidovudine was approved by the FDA on March 19, 1987, with other antiretroviral agents for the treatment of HIV infection in adults and in children 3 months of age or older. This medicine is also approved for use in HIV infected women to prevent the virus from being passed to their babies during pregnancy and delivery. It is then given to these babies for the first 6 weeks of life. Although the FDA does not approve this practice, zidovudine may be used to prevent workers from getting HIV infection after they accidentally come into contact with the virus on the job. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Pregnant women living with HIV may not receive the recommended treatment

Pregnant women living with HIV may not receive the recommended treatment

First epoetin alfa biosimilar receives FDA approval to treat certain types of anemia

First epoetin alfa biosimilar receives FDA approval to treat certain types of anemia

UNC-Chapel Hill researchers find undesirable issues with widely-used drug screening tool

UNC-Chapel Hill researchers find undesirable issues with widely-used drug screening tool

CCNY scientists develop rapid method for preparing molecules with potential against HIV

CCNY scientists develop rapid method for preparing molecules with potential against HIV

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn's Akynzeo for CINV prevention receives EC approval

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Key HIV drug prices continue to fall, but newer medicines still priced too high

Key HIV drug prices continue to fall, but newer medicines still priced too high

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

Discovery provides clues for potentially eliminating HIV infection in children

Discovery provides clues for potentially eliminating HIV infection in children

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Combination regimens trump monotherapy in fight against HIV transmission

Combination regimens trump monotherapy in fight against HIV transmission

Study explores links between antiretroviral prophylaxis, cleft lip and palate

Study explores links between antiretroviral prophylaxis, cleft lip and palate

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

WHO approves three Mylan ARV therapies to treat HIV/AIDS

WHO approves three Mylan ARV therapies to treat HIV/AIDS

Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease

Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease